News | November 15, 2022
Orchid Pharma reports positive EBIDTA in Q2
The company is focussed on increasing the capacity utilizations while controlling costs
The company is focussed on increasing the capacity utilizations while controlling costs
Nikon’s newly launched product AXR Point scanning confocal microscope provides “World’s largest Field of View” of 25mm in one single shot
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The company is making its entry into the Hyderabad market through its unique asset-light business model
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
The Group will continue to make proactive investments of its management resources in the life science business
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Subscribe To Our Newsletter & Stay Updated
